Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer

The Prostate ◽  
2015 ◽  
Vol 75 (6) ◽  
pp. 637-645 ◽  
Author(s):  
Tilman Todenhöfer ◽  
Jörg Hennenlotter ◽  
Frank Faber ◽  
Diethelm Wallwiener ◽  
David Schilling ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Tumor Cells ◽  
Disseminated Tumor Cells ◽  
Localized Prostate Cancer

scholarly journals Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer

The Prostate ◽  
2019 ◽  
Vol 79 (14) ◽  
pp. 1715-1727 ◽  
Author(s):  
Frank C. Cackowski ◽  
Yugang Wang ◽  
Joseph T. Decker ◽  
Christopher Sifuentes ◽  
Steven Weindorf ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Tumor Cells ◽  
Disseminated Tumor Cells ◽  
Localized Prostate Cancer

Perioperative Activation of Disseminated Tumor Cells in Bone Marrow of Patients With Prostate Cancer

2009 ◽  
Vol 27 (10) ◽  
pp. 1549-1556 ◽  
Author(s):  
Dorothea Weckermann ◽  
Bernhard Polzer ◽  
Thomas Ragg ◽  
Andreas Blana ◽  
Günter Schlimok ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Tumor Cells ◽  
Cox Regression ◽  
Systemic Disease ◽  
Disseminated Tumor Cells ◽  
Comparative Genomic ◽  
Prognostic Impact ◽  
Primary Tumors ◽  
Cox Regression Analysis

Purpose The outcome of prostate cancer is highly unpredictable. To assess the dynamics of systemic disease and to identify patients at high risk for early relapse we followed the fate of disseminated tumor cells in bone marrow for up to 10 years and genetically analyzed such cells isolated at various stages of disease. Patients and Methods Nine hundred bone marrow aspirates from 384 patients were stained using the monoclonal antibody A45-B/B3 directed against cytokeratins 8, 18, and 19. Log-rank statistics and Cox regression analysis were applied to determine the prognostic impact of positive cells detected before surgery (244 patients) and postoperatively (214 patients). Samples from primary tumors (n = 55) and single disseminated tumor cells (n = 100) were analyzed by comparative genomic hybridization. Results Detection of cytokeratin-positive cells before surgery was the strongest independent risk factor for metastasis within 48 months (P < .001; relative risk [RR], 5.5; 95% CI, 2.4 to 12.9). In contrast, cytokeratin-positive cells detected 6 months to 10 years after radical prostatectomy were consistently present in bone marrow with a prevalence of approximately 20% but had no influence on disease outcome. Characteristic genotypes of cytokeratin-positive cells were selected at manifestation of metastasis. Conclusion Cytokeratin-positive cells in the bone marrow of prostate cancer patients are only prognostically relevant when detected before surgery. Because we could not identify significant genetic differences between pre- and postoperatively isolated tumor cells before manifestation of metastasis, we postulate the existence of perioperative stimuli that activate disseminated tumor cells. Patients with cytokeratin-positive cells in bone marrow before surgery may therefore benefit from adjuvant therapies.

scholarly journals Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications—An Immunocytochemical Study

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Nigel P. Murray ◽  
Eduardo Reyes ◽  
Pablo Tapia ◽  
Leonardo Badínez ◽  
Nelson Orellana
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Matrix Metalloproteinase ◽  
Tumor Cells ◽  
Gleason Score ◽  
Stromal Cells ◽  
Disseminated Tumor Cells ◽  
Matrix Metalloproteinase 2 ◽  
Low Grade ◽  
Immunocytochemical Study

Matrix metalloproteinase-2 (MMP-2) is important in the dissemination and invasion of tumor cells and activates angiogenesis. We present an immunocytochemical study of MMP-2 expression in circulating prostate cells (CPCs), disseminated tumor cells (DTCs), and micrometastasis (mM) in bone marrow of men with prostate cancer. Methods and Patients. Tumor cells were identified with anti-PSA immunocytochemistry. Positive samples underwent processing with anti-MMP-2, its expression was compared with Gleason score, concordance of expression, and metastatic and nonmetastatic disease. Results. 215 men participated, CPCs were detected in 62.7%, DTCs in 62.2%, and mM in 71.4% in nonmetastatic cancer; in metastatic cancer all had CPCs, DTCs, and mM detected. All CPCs and DTCs expressed MMP-2; in mM MMP-2 expression was positively associated with increasing Gleason score. MMP-2 expression in CPCs and DTCs showed concordance. In low grade tumors, mM and surrounding stromal cells were MMP-2 negative, with variable expression in high grade tumors; in metastatic disease, both mM and stromal cells were MMP-2 positive. Conclusions. CPCs and DTCs are different from mM, with inhibition of MMP-2 expression in mM of low grade tumors. With disease progression, MMP-2 expression increases in both mM and surrounding stromal cells, with implications for the use of bisphosphonates or MMP-2 inhibitors.

Prognostic Significance of Disseminated Tumor Cells in the Bone Marrow of Prostate Cancer Patients Treated With Neoadjuvant Hormone Treatment

2008 ◽  
Vol 26 (30) ◽  
pp. 4928-4933 ◽  
Author(s):  
Jens Köllermann ◽  
Steffen Weikert ◽  
Martin Schostak ◽  
Carsten Kempkensteffen ◽  
Klaus Kleinschmidt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Radical Prostatectomy ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Prognostic Significance ◽  
Specific Antigen ◽  
Disseminated Tumor Cells ◽  
Significant Prognostic Factor

Purpose To explore whether the presence of occult disseminated tumor cells (DTCs) in the bone marrow before neoadjuvant hormone therapy influences the prognosis of patients with organ confined prostate cancer treated by radical prostatectomy. Patients and Methods Pretreatment bone marrow aspirates from 193 cT (1-4) pN0M0 prostate cancer patients submitted to neoadjuvant hormone therapy (mean, 8 months) followed by radical prostatectomy were immunohistochemically evaluated by anticytokeratin antibody A45-B/B3 previously validated for the detection of DTCs. Bone marrow status was compared with established clinical and histopathologic risk parameters. Patients’ outcome was evaluated using prostate-specific antigen (PSA) blood serum measurements as surrogate marker for recurrence over a median follow-up of 44 months. Results DTCs were detected in 44.6% of patients. Bone marrow status neither correlated with tumor grade and stage, nor with the pretreatment PSA risk category (all P values > .05). In the univariate Kaplan-Meier analysis, the presence of DTCs was a significant prognostic factor with respect to poor PSA progression-free survival (log-rank test P = .0035). Using a multivariable piecewise Cox regression model, the presence of DTCs was an independent predictor of PSA relapse (relative risk 1.82; P = .014). Conclusion The presence of DTCs in the bone marrow of patients with prostate cancer before neoadjuvant hormone therapy and subsequent surgery represents an independent prognostic parameter, suggesting that DTCs may contribute to the failure of current neoadjuvant hormone therapy regimens.

scholarly journals Abstract 3916: Disease-specific markers may be used for the identification of disseminated tumor cells in the bone marrow of patients with prostate cancer

2017 ◽  
Author(s):  
Emma E. van der Toom ◽  
Stephanie A. Glavaris ◽  
Michael A. Gorin ◽  
James A. Verdone ◽  
Kenneth J. Pienta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Tumor Cells ◽  
Disseminated Tumor Cells ◽  
Disease Specific

COMPARISON OF RT-PCR AND IMMUNOCYTOCHEMISTRY FOR THE DETECTION OF DISSEMINATED TUMOR CELLS IN BONE MARROW AND BLOOD OF PATIENTS WITH PROSTATE CANCER

1999 ◽  
pp. 243
Author(s):  
Ralph Oberneder ◽  
Alexandra Radaj ◽  
Rainer Riesenberg ◽  
Alex Buchner ◽  
Klaus Pantel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Tumor Cells ◽  
Disseminated Tumor Cells ◽  
Rt Pcr
Sign in / Sign up

Export Citation Format

Share Document